CJC-1295
CJC-1295 No DAC, also called Modified GRF 1-29, is a short-acting lab-made copy of growth-hormone-releasing hormone (GHRH), the body's signal to release growth hormone. Published human studies cover the parent CJC-1295 compound, and no large trial has tested the No DAC version.
At a glance
- Hormone-related
- subcutaneous
- Expert commentaryExpert commentary, across 2 audits
- 200 mcg per Peptide Dosing Protocols. All 3 sources
- 10 mg in 3 mL
How much to draw
Full calculator →Opened on 200 mcg, the figure Peptide Dosing Protocols reports for CJC-1295, and a 10 mg vial in 3 mL. A reported amount, not a recommendation. Change any number to match the vial in your hand. How to reconstitute a vial.
What sources report
These are figures published elsewhere, reproduced with their source. Peppersite does not recommend an amount for CJC-1295 or for anything else, and nothing below has been checked against the study it came from.
| Amount | Frequency | Route | Reported by |
|---|---|---|---|
| 100 mcg per injection (1-2 mcg/kg saturation dose) | 2-3 times daily8-12 weeks | subcutaneous | Peptide Protocol Wiki |
| Standard: 200 mcg, once daily · Low: 100 mcg, once daily · High: 300 mcg, up to 3x daily | 1-3 times daily8-12 weeks · 4-6 weeks off | Subcutaneous (SubQ) | Peptide Dosing ProtocolsWhat it saysHideHalf-life: About 30 minutes. The standard dose is 200 mcg, administered once daily. |
| Non-DAC version referenced at 100-300 mcg (0.1-0.3 mg) per dose due to short half-life. Empty stomach preferred; avoid co-administration with carbohydrates or fats (insulin interference with GH release). | 1-3x daily · Morning, pre-workout, or before bedOn-cycle 8-12 weeks, off-cycle 6-12 weeks | subcutaneous | Peptide Therapy Reference TextWhat it saysHideAug 2026), secondary reference; provider confirmation required. |
- 2-3 times daily8-12 weeks
- subcutaneous
- Peptide Protocol Wiki
- 1-3 times daily8-12 weeks · 4-6 weeks off
- Subcutaneous (SubQ)
- Peptide Dosing Protocols
What it saysHide
Half-life: About 30 minutes. The standard dose is 200 mcg, administered once daily.
- 1-3x daily · Morning, pre-workout, or before bedOn-cycle 8-12 weeks, off-cycle 6-12 weeks
- subcutaneous
- Peptide Therapy Reference Text
What it saysHide
Aug 2026), secondary reference; provider confirmation required.
- Bacteriostatic water
- 10 mg vial with 3 mL bacteriostatic water
You will almost never hear ipamorelin mentioned without CJC-1295, and there is a real reason researchers pair them.
Your COA Says 99.9%. That Number Can Be True and the Vial Still Be Short.
Purity tells you the composition of what's in the vial. It says nothing about how much is in there, and almost every certificate published to buyers answers the first question and quietly skips the second.
Tesamorelin Is Approved. CJC-1295 Is Living Off Its Reputation.
The GH-axis peptides are not one evidence base, they're a steep ladder, and the rung most buyers think they're standing on isn't the one they're on.
How it is thought to work
CJC-1295 No DAC prompts the pituitary gland to release one short burst of growth hormone, then clears the body in about 30 minutes. Researchers link this to GHRH receptor signaling, the same pathway the body's own signal uses, while the DAC version binds albumin and keeps growth hormone raised for days. Human studies cover the parent CJC-1295 sequence, and no large trial or multi-year safety data exists for the No DAC version.
GHRH receptor signaling; GH axis modulation.
What we don't know
The No DAC version: no large clinical trial has been run on it. The published human studies cover the parent CJC-1295 compound.
Long-term safety: no multi-year human safety data exists for the No DAC version. Long-term effects on insulin sensitivity and blood sugar are not well studied.
Outcomes beyond hormone levels: a review covered in our audit says the evidence for this class of peptides runs from regulatory-grade trial data to no human studies at all. It calls the performance and body-recomposition benefits uncertain.
Reported side effects
Seen in studies: a 2006 Phase 2 trial of the DAC version in HIV patients was halted after a participant had a heart attack. Investigators said the event was unrelated, but the program was discontinued. No similar signal has been reported for the No DAC version, which has no large trial of its own.
Reported by users: mild flushing or warmth shortly after injection, mild short-lived headache, redness or irritation at the injection site, mild water retention, and tingling or numbness in the hands. Most effects are described as passing within 30-60 minutes, and higher single doses tend to bring more flushing and headache.
Not ruled out: long-term effects on insulin sensitivity and blood sugar, which are not well studied. Long-term IGF-1 elevation has theoretical implications for cell growth. Purity and identity vary by supplier, because it is sold as a research compound.
Who should avoid it
People with active or recent cancer: growth hormone and IGF-1 can affect cell growth.
People with meaningful cardiovascular disease, especially uncontrolled heart conditions: listed as a caution in the reference library, with no reason given.
People who are pregnant or breastfeeding: listed as a caution in the reference library, with no reason given.
People with significant glucose problems or uncontrolled diabetes: growth hormone can raise blood sugar.
People with known hypersensitivity to peptide products or to bacteriostatic water (benzyl alcohol): listed as a caution in the reference library, with no reason given.
People on glucocorticoids (steroids): these can blunt the growth hormone response.
People on insulin or oral diabetes medicines: these may interact with glucose changes driven by growth hormone.
People on thyroid medicines: growth hormone affects thyroid hormone conversion, so adjustments may be relevant.
What gets monitored
IGF-1 at baseline and again at 4-6 weeks; fasting glucose and HbA1c due to potential blood sugar elevation. (reported by Peptide Dosing Protocols)
Regulatory status
FDA approval: CJC-1295 is not FDA-approved for any use, with or without DAC.
Development history: a 2006 Phase 2 trial of the DAC version in HIV patients was halted after a cardiac event in a participant. Investigators said the event was unrelated, but the program was discontinued.
Supply: it is sold as a research compound, and purity and identity vary by supplier. A review covered in our audit notes that product composition is uncertain in unregulated supply chains.
Checked: November 2026.
Common questions
What is CJC-1295 No DAC?
CJC-1295 No DAC is a short-acting copy of growth-hormone-releasing hormone (GHRH). It prompts the pituitary gland to release a single pulse of growth hormone. It is also called Modified GRF 1-29 or Mod GRF 1-29.
What is the common starting dose for CJC-1295 No DAC?
Reported amounts and schedules for CJC-1295 differ by source, and peppersite does not recommend one. Each reported figure is listed in the dosing rows on this page, next to the source that reports it.
What is CJC-1295 No DAC's half-life?
About 30 minutes. Each dose creates one short pulse and then fades.
How do you reconstitute a 10 mg CJC-1295 No DAC vial?
That depends on the vial size and how much water is added. The calculator on this page works out the draw for any combination, and the reconstitution guide covers the steps.
How is CJC-1295 No DAC different from CJC-1295 with DAC?
The No DAC version is short-acting and is usually described as dosed daily. The DAC version binds albumin and lasts 6-8 days, keeping growth hormone raised for days.
Why is CJC-1295 No DAC paired with Ipamorelin?
The two act on the pituitary through different pathways at the same time. CJC-1295 No DAC works through the GHRH receptor and ipamorelin through the ghrelin (GHS) receptor. The source describes this as complementary stimulation that gives a larger growth hormone pulse.
What are the most common side effects?
Commonly reported effects include flushing, headache, injection-site redness and mild water retention. Most are described as passing within 30-60 minutes of a dose.
Is CJC-1295 No DAC FDA-approved?
No. It is not FDA-approved for any use. No large clinical trial has been run on the No DAC version.
Sources
- 01Teichman et al. 2006 (JCEM, Phase 1)
- 02Ionescu and Frohman 2006 (JCEM)
- 03Alba et al. 2006 (preclinical)
- 04Jette et al. 2005 (Endocrinology)
- 05ConjuChem Phase 2, 2006 (NCT00267527, DAC version)
The reference sections on this page come from a compound library we import, not from our own review of the studies. Our own evidence grade appears only where an audit is linked. Research use only; nothing here is medical advice or a protocol.
Sermorelin is a lab-made peptide that copies the first 29 amino acids of the body's own growth hormone-releasing hormone (GHRH). It has been studied in the growth hormone system, including FDA-era trials as a diagnostic agent and as a treatment for growth hormone deficiency in children.
MOTS-c is a short chain of 16 amino acids that cells build from mitochondrial DNA rather than from the DNA in the nucleus. Most of what is known about it comes from cell and animal work on metabolism, exercise capacity and insulin sensitivity.
This is a combination of two growth hormone compounds sold in a single vial: tesamorelin, a synthetic copy of growth hormone-releasing hormone, and ipamorelin, a ghrelin mimic that acts as a growth hormone secretagogue. It is sold for research use and is studied in the context of the growth hormone system, visceral fat and recovery.
Glutathione (GSH) is a small molecule built from three amino acids, cysteine, glycine and glutamate, made by nearly every cell and most of all by the liver. It has been studied in people for skin lightening, liver enzymes in fatty liver disease, and Parkinson's disease.
Tirzepatide is a lab-made peptide that switches on two gut-hormone receptors, GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1). It is studied in people for weight management and blood sugar control, including in the SURPASS and SURMOUNT trial programs.
5-Amino-1MQ (5-amino-1-methylquinolinium) is a small lab-made molecule, not a true peptide, though it is often sold alongside research peptides. It is studied for shrinking fat cells and raising NAD+ levels, and all evidence so far comes from cell and rodent studies, with no published human trial.